Erratum: Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study (The Lancet (2011) 377(9763) (393–402) (S0140673610609592) (10.1016/S0140-6736(10)60959-2));Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study

The Lancet

Volumn 377, Issue 9763, 2011, Pages 393-402

  Cheng, Gregory ^a   Saleh, Mansoor N ^b   Marcher, Claus ^c   Vasey, Sandra ^d   Mayer, Bhabita ^e   Aivado, Manuel ^d   Arning, Michael ^d   Stone, Nicole L ^d   Bussel, James B ^f  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Georgia Cancer Specialists   (United States)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; PLACEBO;

ABDOMINAL DISTENSION; ADULT; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; CATARACT; CELLULITIS; CLINICAL TRIAL; COLON CANCER; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; DYSPEPSIA; ECCHYMOSIS; EPISTAXIS; EYE SWELLING; FACE EDEMA; FALLING; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLUENZA; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NECK PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SORE THROAT; SPLENECTOMY; TACHYCARDIA; THORAX PAIN; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VOMITING;

EID: 79251583872     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60129-3     Document Type: Erratum

References (39)

1. F Rodeghiero, R Stasi, T Gernsheimer Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group Blood 113 2009 2386 2393
2. DM Arnold, JG Kelton Current options for the treatment of idiopathic thrombocytopenic purpura Semin Hematol 44 2007 S12 S23
3. W Stevens, H Koene, JJ Zwaginga, G Vreugdenhil Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights Neth J Med 64 2006 356 363
4. N Cooper, J Bussel The pathogenesis of immune thrombocytopaenic purpura Br J Haematol 133 2006 364 374
5. DB Cines, JB Bussel How I treat idiopathic thrombocytopenic purpura (ITP) Blood 106 2005 2244 2251
6. JB Bussel, G Cheng, MN Saleh Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura N Engl J Med 357 2007 2237 2247
7. JB Bussel, D Provan, T Shamsi Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial Lancet 373 2009 641 648
8. JB Bussel, DJ Kuter, JN George AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP N Engl J Med 355 2006 1672 1681
9. JB Bussel, DJ Kuter, V Pullarkat, RM Lyons, M Guo, JL Nichol Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP Blood 113 2009 2161 2171
10. DJ Kuter, JB Bussel, RM Lyons Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial Lancet 371 2008 395 403
11. A Newland, MT Caulier, M Kappers-Klunne An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura Br J Haematol 135 2006 547 553
12. R Stasi, ML Evangelista, S Amadori Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura Drugs 68 2008 901 912
13. JB Bussel, B Psaila, MN Saleh Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura Blood 112 2008 3431
14. JB Bussel, G Cheng, MN Saleh Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura Blood 112 2008 3432
15. JG McHutchison, G Dusheiko, ML Shiffman Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C N Engl J Med 357 2007 2227 2236
16. A Baranwal, L Fraser, D Jayawardene, A Jagiello-Gruszfeld, I Bondarenko, J Mendoza Efficacy and safety of eltrombopag, a novel, oral platelet growth factor on platelet counts in patients with cancer receiving carboplatin/ paclitaxel chemotherapy Support Care Cancer 15 2007 761 Abstr P-168.
17. JN George, SH Woolf, GE Raskob Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology Blood 88 1996 3 40
18. British Committee for Standards in Haematology General Haematology Task Force Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy Br J Haematol 120 2003 574 596
19. JE Ware, M Kosinski, JE Dewey How to score version two of the SF-36 health survey 2000 QualityMetric, Incorporated Lincoln, RI, USA
20. D Cella, S Yount, M Sorensen, E Chartash, N Sengupta, J Grober Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis J Rheumatol 32 2005 811 819
21. JS Lai, D Cella, CH Chang, RK Bode, AW Heinemann Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale Qual Life Res 12 2003 485 501
22. D Cella, JL Beaumont, KA Webster, JS Lai, L Elting Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy - thrombocytopenia (FACT-Th) questionnaire Support Care Cancer 14 2006 1220 1231
23. SE Fehnel, CM Bann, SL Hogue, WJ Kwong, SS Mahajan The development and psychometric evaluation of the Motivation and Energy Inventory (MEI) Qual Life Res 13 2004 1321 1336
24. K-Y Liang, SL Zeger Longitudinal data analysis using generalised linear models Biometrika 73 1986 13 22
25. R Stasi, G Cheng, MN Saleh Durable and overall platelet responses in patients with chronic idiopathic thrombocytopenic purpura during long-term treatment with oral eltrombopag by splenectomy status: the RAISE study Haematologica 94 2009 3 Abstr 0231.
26. PROMACTA (eltrombopag) tablets, for oral use. Package insert 2010 GlaxoSmithKline Research Triangle Park, NC, USA
27. TB Gernsheimer, JN George, LM Aledort Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP) J Thromb Haemost 2010 10.1111/j.1538-7836.2010. 03830.x published online March 3.
28. A Sarpatwari, D Bennett, JW Logie Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database Haematologica 95 2010 1167 1175
29. S Zelcer, JB Bussel Thrombosis in patients with immune thrombocytopenic purpura (ITP): a case series J Thromb Haemost 1 2003 abstr P1169.
30. JB Bussel, G Cheng, MN Saleh, S Vasey, M Aivado, A Brainsky Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura Blood 114 2009 abstr 2423.
31. MN Saleh, JB Bussel, G Cheng Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND study Blood 114 2009 abstr 682.
32. MN Saleh, JB Bussel, O Meyer Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag Blood 114 2009 abstr 1326.
33. K Grotzinger, A Matzdorff, TM Brown, R Horblyuk, A Brainsky Corticosteroids for the treatment of chronic idiopathic thrombocytopenic purpura: patient-perceived burden Haematologica 94 2009 96 Abstr 0242.
34. A Matzdorff, G Arnold Treatment of chronic immune thrombocytopenic purpura: the patients' perspective Eur J Haematol 78 2007 381 388
35. JE Portielje, RG Westendorp, HC Kluin-Nelemans, A Brand Morbidity and mortality in adults with idiopathic thrombocytopenic purpura Blood 97 2001 2549 2554
36. DM Boruchov, S Gururangan, MC Driscoll, JB Bussel Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP) Blood 110 2007 3526 3531
37. JN George Management of patients with refractory immune thrombocytopenic purpura J Thromb Haemost 4 2006 1664 1672
38. B Psaila, JB Bussel Refractory immune thrombocytopenic purpura: current strategies for investigation and management Br J Haematol 143 2008 16 26
39. A Reiner, T Gernsheimer, SJ Slichter Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura Blood 85 1995 351 358